Trials / Completed
CompletedNCT00880308
Dose Finding and Safety of Oral LDE225 in Patients With Advanced Solid Tumors
A Phase I, Multicenter, Open-label, Dose-escalation Study of Oral LDE225 in Patients With Advanced Solid Tumors
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 103 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This first-in-human dose-escalation study is to characterize the safety, tolerability, pharmacokinetics and pharmacodynamics of LDE225 given orally on a daily dosing schedule in patients with advanced solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LDE225 |
Timeline
- Start date
- 2009-03-01
- Primary completion
- 2013-07-01
- Completion
- 2013-07-01
- First posted
- 2009-04-13
- Last updated
- 2020-12-19
Locations
5 sites across 4 countries: United States, Spain, Switzerland, United Kingdom
Source: ClinicalTrials.gov record NCT00880308. Inclusion in this directory is not an endorsement.